Fascin Inhibitors Decrease Cell Migration and Adhesion While Increase Overall Survival of Mice Bearing Bladder Cancers

Bladder cancer is one of the most common cancers in the world. Early stage bladder tumors can be surgically removed, but these patients usually have relapses. When bladder cancer becomes metastatic, survival is very low. There is an urgent need for new treatments for metastatic bladder cancers. Here...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 13; no. 11; p. 2698
Main Authors Zhao, Zhankui, Wang, Yufeng, Zhang, J. Jillian, Huang, Xin-Yun
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 30.05.2021
MDPI
Subjects
Actin
anti-PD-1
Apoptosis
Binding sites
Bladder cancer
Breast cancer
Cancer
Cancer therapies
Cell adhesion & migration
Cell growth
Cell migration
Chemotherapy
Cisplatin
cytoskeleton
fascin
Immune checkpoint inhibitors
Investigations
Medical prognosis
Metastases
Metastasis
Patients
PD-1 protein
Tumor cells
tumor metastasis
Tumors
Online AccessGet full text

Cover

More Information
Summary:Bladder cancer is one of the most common cancers in the world. Early stage bladder tumors can be surgically removed, but these patients usually have relapses. When bladder cancer becomes metastatic, survival is very low. There is an urgent need for new treatments for metastatic bladder cancers. Here, we report that a new fascin inhibitor decreases the migration and adhesion of bladder cancer cells. Furthermore, this inhibitor decreases the primary tumor growth and increases the overall survival of mice bearing bladder cancers, alone, as well as in combination with the chemotherapy medication, cisplatin, or the immune checkpoint inhibitor, anti-PD-1 antibody. These data suggest that fascin inhibitors can be explored as a new treatment for bladder cancers.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Department of Urology, Affiliated Hospital of Jining Medical University, Jining 272029, China.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13112698